Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
Kathleen Dooling(Pfizer (United States)), Sara E. Oliver(Centers for Disease Control and Prevention), Danielle Moulia(Centers for Disease Control and Prevention), Oliver Brooks, Hannah G. Rosenblum(National Center for Immunization and Respiratory Diseases), Jack Gerstein, Heidi L. Moline(Centers for Disease Control and Prevention), Julia W. Gargano(Canadian Institutes of Health Research), Stephen C. Hadler(The Task Force for Global Health), Monica Godfrey, Grace M. Lee, Amy Blain, H. Keipp Talbot(Marshfield Clinic), Rebecca L. Morgan(Impact), Ian D. Plumb(Centers for Disease Control and Prevention), Doug Campos‐Outcalt, Megan Wallace(Centers for Disease Control and Prevention), Jennifer P. Collins(Emory University), Matthew F. Daley(Kaiser Permanente)
Cited by 41
Related Papers
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
|The Lancet|2019|1.3k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602
Sexually Transmitted Infections Among US Women and Men: Prevalence and Incidence Estimates, 2018
|Sexually Transmitted Diseases|2021|535
Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021
|Preventing Chronic Disease|2021|370